Drugmaker

Largest PE investment in Indian pharma: KKR injects $200 mn into Gland Pharma

KKR'S latest investment in India underscores the positive outlook for generic drugmakers, despite some concerns about manufacturing quality after the recent crackdown by overseas regulators including the US Food and Drug Administration.<br /><br />

US to hike fees for generic drugmakers from Oct; Indian firms to be hit

Many Indian drugmakers will soon have to bear higher costs for sale of products in American markets, as the US health regulator FDA is hiking the fees for generic drugmakers by up to 48 percent from October.

Cipla offers to buy majority stake in S.Africa's Cipla Medpro

Indian drugs maker Cipla Limited has offered to buy a about a 51% stake in South Africa's Cipla Medpro, to strengthen its position in the fast-growing African drugs market.<br /><br /> <br /><br /> The Indian firm has offered 8.55 rand per share, Cipla Medpro said in a statement on Wednesday. The price represents an 11% premium on Cipla Medpro's closing share price on Tuesday. That makes the deal worth around $220 million.<br /><br /> <br /><br /> <br /><br /> <br /><br /> Also Read<br /><br /> <br /><br /> Related Stories <br /><br /> <br /><br /> News Now <br /><br /> - Cipla gains on acquisition plan of Cipla Medpro<br /><br /> - RTI offers roundabout route to India Inc info<br /><br /> - Wkly Tech Analysis: Nifty may drop to 5,470<br /><br /> - Nifty may drop to 5,470<br /><br /> - The ride will not be easy<br /><br /> - Short-term bias seems negative<br /><br /> Shares of Cipla Medpro, South Africa's No.3 drug maker, surged 8.58% to 8.35 rand on the news.<br /><br /> <br /><br /> Cipla supplies the bulk of Cipla Medpro's drugs through a longstanding supply agreement. However, the two have never had a capital alliance.<br /><br /> <br /><br /> The agreement was spearheaded by Cipla Medpro's founder and former chief executive, Jerome Smith, who quit last month following charges of "gross misconduct" for approving pay rises and bonsues for himself with board approval.<br /><br /> There had been some speculation in the market that Smith's departure could impact Cipla Medpro's relationship with the Indian company.

Drugmaker Cipla to set up Rs 225 cr manufacturing plant in Iran

Setting up the plant will help in faster registrations of new products and will improve its competitive position, the company said, adding it does not expect any impact on its U.S. and European businesses due to its investments in Iran.<br />

All-cash deal: Roche to buy US biotech firm InterMune for $8.3 bn

Roche Holding AG has agreed to buy US biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector.<br />

Indian drugmakers to pay 12-15% higher facility fees as USFDA hikes rates

The US laws authorise the drug and health watchdog to assess and collect user fees for certain applications and supplements for human generic drug products.<br />